Idera squelch­es any lin­ger­ing en­thu­si­asm as its lead TLR9 drug flunks PhI­II — bad­ly

More than 3 years ago, with its stock rid­ing high, Idera $IDRA caused quite a stir at ES­MO with its TLR9 drug and the 44% ORR it tracked in a hand­ful of pa­tients suf­fer­ing from ad­vanced melanoma. The ORR for the Toll-like re­cep­tor 9 ag­o­nist dropped to 22% in Phase II. And on Thurs­day, the Phase III — its lead pro­gram — came out with a mis­er­able 8.8% ORR for its com­bo ap­proach us­ing ip­il­i­mum­ab.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.